HCPCS Code Q5104: Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg

HCPCS code Q5104 is for the injection of infliximab-abda, a biosimilar of Renflexis 10 mg, used in the management of autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Infliximab abda treats autoimmune diseases like rheumatoid arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis by reducing inflammation and targeting tumor necrosis factor alpha in patients with active disease or inadequate response to conventional therapy.

Renflexis infusion average Medicare reimbursement is approximately $30.87 per 10 mg unit, but varies by payer, site of service, and systemic therapy protocols.

Remicade is the original infliximab drug, while infliximab biosimilars like Renflexis are similar versions with the same active ingredient. Providers use them interchangeably based on medical necessity, patient tolerance, and payer coverage.